Trial Profile
Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Advanced breast cancer; Anal cancer; Cervical cancer; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Nasopharyngeal cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- Acronyms INSPIRE
- 18 Dec 2023 Last checked against ClinicalTrials.gov record.
- 06 Dec 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 06 Dec 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.